GSK-Pfizer Owned ViiV Healthcare Received A Positive Opinion From The European Medicines Agency's CHMP Recommending Approval Of Cabotegravir Long-acting Injectable And Tablets For HIV Prevention
Portfolio Pulse from Benzinga Newsdesk
ViiV Healthcare, owned by GSK and Pfizer, has received a positive opinion from the European Medicines Agency's CHMP recommending approval of Cabotegravir long-acting injectable and tablets for HIV prevention.
July 24, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's subsidiary ViiV Healthcare received a positive opinion from the EMA's CHMP for its HIV prevention drug, which could potentially boost GSK's revenues.
As a major stakeholder in ViiV Healthcare, GSK stands to benefit from the potential approval and subsequent sales of Cabotegravir. This could lead to increased revenues for GSK, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, as a part-owner of ViiV Healthcare, could see a potential increase in revenues following the positive opinion from the EMA's CHMP for the HIV prevention drug.
Pfizer, being a part-owner of ViiV Healthcare, could benefit from the potential approval and subsequent sales of Cabotegravir. This could lead to increased revenues for Pfizer, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80